7-溴-1-氯异喹啉 | 215453-51-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 7-溴-1-氯异喹啉
• 中文别名: 1-氯-7-溴异喹啉
• 英文名称: 7-bromo-1-chloroisoquinoline
• CAS: 215453-51-3
• 化学式: C₉H₅BrClN
• 分子量: 242.502
• InChiKey: UMSWWSIVPWVJOX-UHFFFAOYSA-N

物化性质

• 熔点：
  126-128°C
• 沸点：
  349.5±22.0 °C(Predicted)
• 密度：
  1.673±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  T
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362+P364,P403+P233,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  保存方法：密闭、阴凉、通风干燥处。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
7-Bromo-1-chloroisoquinoline
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
7-Bromo-1-chloroisoquinoline
Ingredient name:
CAS number: 215453-51-3

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H5BrClN
Molecular weight: 242.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (7-Bromo-1-chloroisoquinoline)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-溴-1-氯异喹啉 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 sodium acetate 作用下， 以 甲醇 、 乙腈 为溶剂， 70.0~130.0 ℃ 、172.37 kPa 条件下， 反应 23.0h， 生成 methyl 1-methoxyisoquinoline-7-carboxylate
  参考文献：
  名称：

  N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS

  摘要：

  这项发明提供了化合物的化学式(I)或其药用可接受的盐；其中G是R1，R2和R3如本文所述；以及其药物组合物；以及在治疗受乙酰辅酶A羧化酶抑制调节的动物疾病、状况或紊乱中的使用。

  公开号：

  US20120108619A1
• 作为产物：
  描述：

  4-溴肉桂酸 在 氯化亚砜 、 sodium azide 、 碘 、 三氯氧磷 作用下， 以 二苯醚 、 水 、 丙酮 、 苯 为溶剂， 反应 12.5h， 生成 7-溴-1-氯异喹啉
  参考文献：
  名称：

  1-氨基-7-(哌啶-4-基)异喹啉的简便合成

  摘要：

  摘要 以 4-溴肉桂酸为原料，开发了 2-氨基-7-(哌啶-4-基)异喹啉的优化合成方法。

  DOI：

  10.1081/scc-200050372

文献信息

• Generation and Cross-Coupling of Organozinc Reagents in Flow
  作者：Ananda Herath、Valentina Molteni、Shifeng Pan、Jon Loren

  DOI：10.1021/acs.orglett.8b03156

  日期：2018.12.7

  formation of organozinc reagents and subsequent cross-coupling with aryl halides and activated carboxylic acids is reported. Formation of organozinc reagents is achieved by pumping organic halides, in the presence of ZnCl2 and LiCl, through an activated Mg-packed column under flow conditions. This method provides efficient in situ formation of aryl, primary, secondary, and tertiary alkyl organozinc reagents

  报道了一种通用的流动合成方法，用于原位形成有机锌试剂，然后与芳基卤化物和活化的羧酸进行交叉偶联。有机锌试剂的形成是通过在流动条件下将有机卤化物在ZnCl 2和LiCl的存在下泵送通过活化的Mg填充柱来实现的。该方法可有效地原位形成芳基，伯，仲和叔烷基有机锌试剂，随后将其在下游进行Negishi或脱羧Negishi交叉偶联反应的伸缩。所描述的方法提供了使用有机锌试剂获得各种C–C键的方法，这些试剂否则在商业上是不可用的，或者在传统的间歇反应条件下难以制备。
• Isoquinolines as urokinase inhibitors
  申请人：Pfizer Inc.

  公开号：US06248738B1

  公开（公告）日：2001-06-19

  Compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is H and the other is N═C(NH2)2 or NHC(═NH)NH2, and the other substituents are as defined herein, are urokinase (uPA) inhibitors.

  式(I)的化合物及其药用盐，其中R1和R2中的一个是H，另一个是NHC(NH2)2或NHC(NH)NH2，其他取代基如本文所定义，是尿激酶（uPA）抑制剂。
• [EN] SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE<br/>[FR] INHIBITEURS À PETITE MOLÉCULE DE KINASE INDUISANT NF-KB
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020239999A1

  公开（公告）日：2020-12-03

  The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

  本发明涉及抑制NIK的化合物，以及包含这些化合物的药物组合物和使用方法。这些化合物和药物组合物预期能用于预防或治疗癌症（如包括白血病、淋巴瘤和多发性骨髓瘤的B细胞恶性肿瘤）、炎症性疾病、自身免疫疾病、免疫皮肤病学疾病（如掌跖脓疱病和化脓性汗腺炎）以及代谢紊乱疾病（如肥胖和糖尿病）。
• [EN] CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2<br/>[FR] ANTAGONISTES DU CCR2 À BASE DE CYCLOHEXYL-AZÉTIDINYLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011159854A1

  公开（公告）日：2011-12-22

  The present invention comprises compounds of Formula (I). Wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括公式(I)的化合物。其中：R1、R2、R4、J、Q和A如说明书所述定义。本发明还包括预防、治疗或改善综合征、障碍或疾病的方法，其中所述综合征、障碍或疾病为2型糖尿病、肥胖和哮喘。本发明还包括通过管理治疗有效量的至少一种公式(I)化合物来抑制哺乳动物中的CCR2活性的方法。
• Inhibitors of the Detoxifying Enzyme of the Phytoalexin Brassinin Based on Quinoline and Isoquinoline Scaffolds
  作者：M. Pedras、Abbas Abdoli、Vijay Sarma-Mamillapalle

  DOI：10.3390/molecules22081345

  日期：——

  The detoxification of the phytoalexin brassinin to indole-3-carboxaldehyde and S-methyl dithiocarbamate is catalyzed by brassinin oxidase (BOLm), an inducible fungal enzyme produced by the plant pathogen Leptosphaeria maculans. Twenty-six substituted quinolines and isoquinolines are synthesized and evaluated for antifungal activity against L. maculans and inhibition of BOLm. Eleven compounds that inhibit BOLm activity are reported, of which 3-ethyl-6-phenylquinoline displays the highest inhibitory effect. In general, substituted 3-phenylquinolines show significantly higher inhibitory activities than the corresponding 2-phenylquinolines. Overall, these results indicate that the quinoline scaffold is a good lead to design paldoxins (phytoalexin detoxification inhibitors) that inhibit the detoxification of brassinin by L. maculans.

  植物病原体Leptosphaeria maculans产生的可诱导真菌酶 brassinin 氧化酶 (BOLm) 催化了植物抗毒素brassinin向indole-3-carboxaldehyde和S-甲基二硫代氨基甲酸的解毒。合成了二十六种取代喹啉和异喹啉，并评估了它们对L. maculans的抑菌活性和对BOLm的抑制作用。报道了十一种抑制BOLm活性的化合物，其中3-乙基-6-苯基喹啉显示出最高的抑制效果。一般来说，取代的3-苯基喹啉比相应的2-苯基喹啉显示出显著更高的抑制活性。总的来说，这些结果表明喹啉支架是设计paldoxins（植物抗毒素解毒抑制剂）的良好先导，可以抑制L. maculans对brassinin的解毒。